• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Vaccine . Lessons from the 2024 avian influenza vaccination campaign in Finland: a qualitative inquiry

tetano

Editor, Senior Moderator
Vaccine


. 2026 May 21:86:128736.
doi: 10.1016/j.vaccine.2026.128736. Online ahead of print.
Lessons from the 2024 avian influenza vaccination campaign in Finland: a qualitative inquiry

Vuokko Härmä[SUP] 1 [/SUP], Minttu Palsola[SUP] 2 [/SUP], Aapo Kuusipalo[SUP] 3 [/SUP], Erika Lindh[SUP] 2 [/SUP], Merit Melin[SUP] 2 [/SUP], Hanna Nohynek[SUP] 2 [/SUP]


Affiliations
Abstract

Highly pathogenicity avian influenza H5N1 (HPAI H5N1) viruses cause a continuous threat to wild avian populations. During recent years, spillover to both wild and domestic mammals has occurred with an increasing frequency. As a consequence of the recent developments in the epidemiological situation, the human-animal interface with the risk of human exposure to HPAI H5 has expanded. In 2024, Finland became a global forerunner to offer H5 vaccine to occupational risk groups, specifically fur and poultry workers, following an extensive HPAI H5N1 outbreak in 2023 in fur-farmed minks and foxes. Despite targeted efforts to reach the people at increased risk, only 8,6% of the target population received the first dose and 7,5% completed both doses. To seek a better understanding of the barriers behind low vaccine uptake a Behavioural and Cultural (BCI) insight approach was chosen. A rapid qualitative study was conducted in late 2024 (n = 17), utilising semi-structured interviews with health authorities, industry stakeholders, and risk group representatives in the Ostrobothnia region in Finland. Barriers were identified across three dimensions: (1) logistical failures, including poor timing and difficulties in reaching target groups (2) divergent risk perceptions, where economic livelihood overshadowed personal health risks; and (3) political distrust, stemming from perceived stigmatization by national health authorities. The results will provide vital information for future pre-pandemic communication and implementation strategies and helps to identify key stakeholders and target groups.

Keywords: Avian influenza; H5N1; Qualitative inquiry; Vaccine hesitancy; Vaccine uptake.

 
Back
Top